Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
Company: Kairos Pharma, LTD.
Filing Date: September 3, 2025
Reporting Period: Current Report (Event Date: September 3, 2025)
Business Context: The Company is a Delaware corporation focused on pharmaceutical development. This filing announces the presentation of initial Phase 1 clinical data for its candidate drug, ENV105, in the treatment of non-small cell lung cancer.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no financial material changes reported in this filing. The material event is the scheduled presentation of clinical trial data by Principal Investigator Dr. Karen Reckamp at the World Lung Cancer Conference (September 6-9, 2025, in Barcelona, Spain).
Outlook, Risks, and Management Commentary
- Management Commentary: The Company highlighted the upcoming presentation of initial Phase 1 data for ENV105 as a key milestone.
- Legal Disclaimer: The information in Item 8.01 and the accompanying press release (Exhibit 99.1) is furnished and not deemed "filed" under Section 18 of the Exchange Act. It is not incorporated by reference into other filings.
- Risks/Contingencies: No specific risks or contingencies are detailed in this text, though clinical trial outcomes inherently carry development risks.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) for specific Phase 1 data results regarding ENV105.
- Confirm the schedule and location of the World Lung Cancer Conference presentation (September 6-9, 2025, Barcelona).
- Review the Company's most recent 10-K or 10-Q filings for current financial status, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the clinical trial results following the conference presentation.